|
|
Dr. Jeffrey Holzbeierlein is the John W. Weigel Endowed Associate Professor of Urology at the University of Kansas Medical Center. He was raised in Edmond, Oklahoma and received his medical degree from the University of Oklahoma. He joined the faculty after completing his internship and residency at Vanderbilt University and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York.
Dr. Holzbeierlein is an active member of the Society of Urologic Oncology where he serves on the Executive Board. He is a member of the South Central Section of the American Urological Association as well as a fellow of the American College of Surgeons. He is a Diplomate of the Board of Urology. He is a founding member and the past chair of the Young Urologic Oncologist Section of the Society of Urologic Oncology and is also a member of the Young Urologists committee for the American Urological Association. He is an Assistant Editor for the Journal of Urology and reviews for a number of other journals including Urology, European Urology, British Journal of Urology, and Urologic Oncology.
Dr. Holzbeierlein serves on numerous hospital committees including the Compliance Committee, the Research Committee for the School of Medicine, and the Board for the Kansas Tissue and Serum Repository. Furthermore, he is active volunteer at the American Cancer Society’s Hope Lodge in downtown Kansas City. Dr. Holzbeierlein was selected as one of Kansas City's 40 Most Promising Residents Under 40 in 2008. He has also been selected as one of Kansas City's Best Doctors since 2006.
Dr. Holzbeierlein has published numerous peer reviewed articles on genitourinary malignancies in a variety of journals, authored several textbook chapters, and gives an annual course on bladder cancer at the American Urological Association meeting.
Dr. Holzbeierlein specializes in the treatment of genitourinary malignancies including prostate, bladder, kidney, testicular, and penile cancers. He has been using new methods such as sural nerve grafting to help decrease side effects of prostate cancer surgery He is also actively involved in basic science research in the area of the androgen receptor in prostate cancer and has received several grants in this area.
|
|
